New version of Tarceva price manual 13621079267 Tarceva domestic purchasing agent website

d%> d= _ d=> A patient with non-small cell lung cancer (NSCLC) who received the third-generation
Indian Tarceva> chemotherapy regimen entered the study and screened out independent prognostic factors: subcutaneous metastasis, low appetite, Lower level, liver metastasis, metastasis site and no previous surgery history. The most praiseworthy and essential part of the "Clinical Diagnosis and Treatment Guidelines for Lung Cancer in China" and the American Comprehensive Cancer Network () lung cancer guidelines published at the end of the year are the staging treatment principles and staging treatment implementation details: Surgery is the preferred treatment for stage I and II lung cancer III. Stage IV lung cancer requires multidisciplinary and organic treatment. Stage IV lung cancer is mainly treated with systemic treatments such as chemotherapy or targeted therapy.
Lung cancer staging is one of the most important clinical prognostic indicators and an extremely important predictor of treatment. It can be seen from this figure that if all unfavorable factors exist with a total score of up to 10%, the corresponding annual survival rate is only .%.
Stage I lung cancer is a fairly large group. According to the principle of staging treatment, the same surgical treatment strategy is used for this group. There are still %~% of patients whose survival time is less than 10 years. These patients actually do not receive individualized treatment. .
A very interesting study is the United States et al.d/_Copy, which established a clinical prediction model based on two large randomized controlled studies of the Eastern Cooperative Oncology Group of the United States.
Although individualized treatment of lung cancer based on clinical factors has taken a big step forward than treatment based solely on experience, it is still not a truly individualized treatment. If there is only one subcutaneous metastasis factor, the corresponding annual survival rate is approximately %. The annual survival rate is less than %. The simplest indicators are the patient's performance status and weight loss index. Developing treatment strategies for lung cancer based on staging is currently recognized as one of the basic standards for individualized treatment. If the body weight loss index is or %, the efficacy of chemotherapy or radiotherapy will be greatly reduced or even counterproductive. From this we can basically determine which patients need active anti-tumor treatment and which patients only need active supportive treatment.
Large-scale clinical trials conducted in recent years have identified some clinical factors as prognostic predictors. The researchers established a clinical model to predict the ~-year survival rate of treatment-naïve patients based on this clinical factor.